Zoetis Inc. (ZTS)
Health Care · Pharmaceuticals · US stock · S&P 500 component
$79.38
▲ +0.96 (1.22%)
Fair valueUndervalued
$164 +106.5% to fair value
$82fair band $115–$213$246
Day's range
$78.29 – $80.59
52-week range
$68.77 – $145.51
About Zoetis Inc.
Zoetis develops, manufactures and sells medicines, vaccines and diagnostic products for pets and farm animals. Its range covers treatments for parasites, pain, skin conditions and infections in dogs and cats, along with products for cattle, pigs and poultry. Revenue comes from selling to veterinarians, distributors and livestock producers around the world, and it depends on pet ownership trends and animal health spending.
The company reported revenue of $9.5 billion for the last twelve months at Zoetis Inc.. Revenue growth over the past three years averaged 5.4% a year. It kept an operating margin of 36.9%. The return on invested capital reached 27%, a measure of profit earned on the money invested in the business. Leverage, measured as net debt to EBITDA, is 1.8 times. The company pays a dividend, and the yield is 2.6%. On the site's X-Ray Score, it rates 68 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $68.77 – $145.51Volume 5,570,700Daily, split-adjusted
Vitals
Market cap$33.2B
52-week range$68.77 – $145.51
Volume (last day)5,570,700
P/E (TTM)13.1
EBIT / EV yield8.7%
Free-cash-flow yield7.0%
Dividend yield2.6%
Revenue (TTM)$9.5B
Net income (TTM)$2.6B
Operating margin36.9%
Return on capital26.7%
Debt incl. leases$9.0B
Cash & securities$1.7B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$164model spread $154 – $176
Undervalued
+106.5% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $79
Undervalued < $115Fair $115 – $213Overvalued > $213
10-year DCF (market-scaled)
$177
Peer multiples
$170
Earnings power floor (not blended)
$59
Fundamentals-adjusted multiple
$145
Growth the price implies
3.4%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Average business at a low price
Our models put fair value above today's price, but models can be wrong, so check the business first. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Strong
87/100
Cheap against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield8.7%
Free-cash-flow yield7.0%
Fair value vs price2.1×
Growth
Weak
48/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)5.4%
EPS growth (3y)10.3%
Growth consistency90%
Profitability
Strong
72/100
Earns high returns on the capital it uses.
See the numbers →
Return on invested capital26.7%
Operating margin36.9%
Gross profitability45.2%
Financial health
Fair
60/100
Balance sheet is in typical shape for its sector.
See the numbers →
Piotroski F-Score6 / 9
Net debt / EBITDA1.8×
Interest cover14.7×
Dividends
Fair
69/100
Dividend is typical for its sector.
See the numbers →
Dividend yield2.6%
Dividends vs free cash flow38%
Dividend growth13.3%
Quarterly results: last 6 quarters
+0.4%
Mar '25
+4.8%
Jun '25
+0.5%
Sep '25
+3.0%
Dec '25
+2.9%
Mar '26
-0.2%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $2.5B, diluted EPS $1.65.
Compare with peers
LLY ELI LILLY & Co61 BMY Bristol Myers Squibb C...59 JNJ Johnson & Johnson50 MRK Merck & Co., Inc.32Other Pharmaceuticals companies by X-Ray Score.
Fundamentals checklist
● 9 Good · ● 6 Average · ● 1 BadCash quality
Earnings backed by cashBad
Free-cash-flow yieldGood
Risk models
Altman Z''Good
Piotroski F-ScoreAverage
Growth
EPS growth (3y)Average
Free-cash-flow growth (3y)Good
Revenue growth (3y)Average
Growth consistencyAverage
Balance sheet
Current ratioGood
Net debt / EBITDAAverage
Interest coverAverage
Valuation
Fair value vs priceGood
EBIT / EV yieldGood
Profitability
Return on invested capitalGood
Operating marginGood
Gross profitabilityGood
Each check is graded against the company's sector, not a fixed number. Checklist score 68/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $7.8B | $8.1B | $8.5B | $9.3B | $9.5B |
| Operating income | $2.7B | $2.9B | $3.2B | $3.4B | $3.6B |
| Net income | $2.0B | $2.1B | $2.3B | $2.5B | $2.7B |
| Operating cash flow | $2.2B | $1.9B | $2.4B | $3.0B | $2.9B |
| Operating margin | 34.9% | 35.6% | 37.2% | 36.3% | 37.8% |
| Free cash flow | $1.7B | $1.3B | $1.6B | $2.3B | $2.3B |
| Diluted EPS | $4.27 | $4.49 | $5.07 | $5.47 | $6.02 |
Fiscal years, from SEC filings.
Technical summary
Daily
Bullish
9 bullish · 1 neutral · 6 bearish
Weekly
Neutral
5 bullish · 1 neutral · 6 bearish
Monthly
Strongly bearish
0 bullish · 1 neutral · 7 bearish
Moving averages (daily)
| SMA 10 | 74.52 | Bullish |
| EMA 10 | 75.23 | Bullish |
| SMA 20 | 72.63 | Bullish |
| EMA 20 | 74.01 | Bullish |
| SMA 50 | 73.98 | Bullish |
| EMA 50 | 74.48 | Bullish |
| SMA 100 | 75.23 | Bullish |
| EMA 100 | 79.44 | Bearish |
| SMA 200 | 95.14 | Bearish |
| EMA 200 | 92.48 | Bearish |
Oscillators (daily)
| RSI (14) | 69.41 | Neutral |
| MACD (12, 26) | 0.98 | Bullish |
| Momentum (12) | 13.68 | Bullish |
| Stochastic %K (14) | 89.76 | Bearish |
| Williams %R (14) | -10.24 | Bearish |
| CCI (20) | 212.6 | Bearish |
Pivot points (classic, last session)
S3 75.95 | S2 77.12 | S1 78.25 | Pivot 79.42 | R1 80.55 | R2 81.72 | R3 82.85 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
2.09 USD
Yield on today's price
2.63%
Frequency
Quarterly
Next ex-dividend date
30 Oct 2026
| Ex-dividend date | Amount per share |
|---|---|
| 30 Oct 2026 (upcoming) | 0.5300 |
| 20 Jul 2026 | 0.5300 |
| 20 Apr 2026 | 0.5300 |
| 20 Jan 2026 | 0.5300 |
| 31 Oct 2025 | 0.5000 |
| 18 Jul 2025 | 0.5000 |
| 21 Apr 2025 | 0.5000 |
| 21 Jan 2025 | 0.5000 |
| 31 Oct 2024 | 0.4320 |
| 18 Jul 2024 | 0.4320 |
| 18 Apr 2024 | 0.4320 |
| 18 Jan 2024 | 0.4320 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
ZTS SEC filings
13 Oct 2026
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
8 Oct 2026
8-KSEC EDGAR
Regulation FD disclosure
6 Aug 2026
10-QSEC EDGAR
Quarterly report
6 Aug 2026
8-KSEC EDGAR
Results of operations
6 Aug 2026
8-KSEC EDGAR
Director or officer change
22 May 2026
8-KSEC EDGAR
Director or officer change; Shareholder vote results
20 May 2026
8-KSEC EDGAR
Regulation FD disclosure
7 May 2026
10-QSEC EDGAR
Quarterly report
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.